Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03687827
Recruitment Status : Completed
First Posted : September 27, 2018
Last Update Posted : March 6, 2020
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes. Participants will be treated with insulin degludec and insulin glargine during two different periods. Which treatment participants get first is decided by chance. Both medicines are approved for use in humans and available on the market. They can already be prescribed by participants' doctors. Participants will get pre-filled insulin pens to inject these insulins with. The study will last for about 41 weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to evaluate the changes in participants' blood sugar level over time, participants will be asked to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants' upper arm 3 times during the study. Each time participants must wear the sensor for 2 weeks. This sensor is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted 5 mm under participants' skin. Please note that participants will not be able to see the sensor readings while wearing it. The study doctor will show participants the readings when participants return to the clinic. Participants will be asked to fill in a diary in between visits. Participants will have contact with the study doctor or study staff each week. This is to adjust the dose of participants' study medicines and to ensure that participants are well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Insulin degludec Drug: Insulin glargine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 498 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring
Actual Study Start Date : October 2, 2018
Actual Primary Completion Date : December 20, 2019
Actual Study Completion Date : December 27, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Insulin degludec
Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
Drug: Insulin degludec
Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
Other Name: Tresiba®

Active Comparator: Insulin glargine
Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
Drug: Insulin glargine
Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
Other Name: Lantus®




Primary Outcome Measures :
  1. Time spent in glycaemic target range 70-180 mg/dL (3.9-10.0 mmol/L) both inclusive, using flash glucose monitoring (FGM) [ Time Frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2) ]
    Measured as percentage of time.


Secondary Outcome Measures :
  1. Time spent in tight glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, using FGM [ Time Frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2) ]
    Measured as percentage of time.

  2. Time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, in the nocturnal period (00:01 am - 05:59 am both inclusive) using FGM [ Time Frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2) ]
    Measured as percentage of time.

  3. Level of glycated haemoglobin (HbA1c) [ Time Frame: After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2) ]
    Measured as percentage of HbA1c.

  4. Mean glucose levels using FGM [ Time Frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2) ]
    Measured as mg/dL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age greater than or equal to 18 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
  • Subjects fulfilling at least one of the below criteria:
  • Experienced at least one severe hypoglycaemic episode within the last year prior to screening (according to the American Diabetes Association definition, January 2018)*
  • Moderate renal impairment defined as estimated glomerular filtration rate value of 30-59 mL/min/1.73 m^2 as defined by Kidney Disease Improving Global Outcomes 2012 at screening
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 at screening
  • Treated with insulin for more than 5 years
  • Episode of hypoglycaemia (defined a glucose alert value of 70 mg/dL (3.9 mmol/L) or less, i.e., Level 1) within the last 12 weeks prior to screening visit
  • Treated with any basal insulin greater than or equal to 90 days prior to the day of screening with or without any of the following anti-diabetic drugs:
  • Metformin
  • Dipeptidyl peptidase-4 inhibitor
  • Sodium-glucose co-transporter 2 inhibitor
  • Alpha-glucosidase-inhibitors (acarbose)
  • Thiazolidinediones
  • Marketed oral combination products only including the products listed above
  • HbA1c less than or equal to 9.5% (80 mmol/mol) at screening confirmed by central laboratory analysis
  • Body mass index less than or equal to 45 kg/m^2 *Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, intermittent bolus insulin treatment for periods of no longer than 14 days are permitted prior to the day of screening
  • Anticipated initiation or change in concomitant medications known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or corticosteroids)
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and run-in

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03687827


Locations
Hide Hide 67 study locations
Layout table for location information
United States, Arizona
Novo Nordisk Investigational Site
Chandler, Arizona, United States, 85224
Novo Nordisk Investigational Site
Tucson, Arizona, United States, 85741
United States, California
Novo Nordisk Investigational Site
Fresno, California, United States, 93720
Novo Nordisk Investigational Site
Lancaster, California, United States, 93534
Novo Nordisk Investigational Site
Northridge, California, United States, 91325
Novo Nordisk Investigational Site
Poway, California, United States, 92064
Novo Nordisk Investigational Site
Van Nuys, California, United States, 91405
United States, Connecticut
Novo Nordisk Investigational Site
Hamden, Connecticut, United States, 06517
United States, Florida
Novo Nordisk Investigational Site
Bradenton, Florida, United States, 34201
Novo Nordisk Investigational Site
Cooper City, Florida, United States, 33024
Novo Nordisk Investigational Site
Hollywood, Florida, United States, 33024
Novo Nordisk Investigational Site
New Port Richey, Florida, United States, 34652
Novo Nordisk Investigational Site
Orlando, Florida, United States, 32825
Novo Nordisk Investigational Site
Pembroke Pines, Florida, United States, 33027
United States, Illinois
Novo Nordisk Investigational Site
Skokie, Illinois, United States, 60077
United States, Kansas
Novo Nordisk Investigational Site
Topeka, Kansas, United States, 66606
United States, Kentucky
Novo Nordisk Investigational Site
Lexington, Kentucky, United States, 40503
Novo Nordisk Investigational Site
Louisville, Kentucky, United States, 40213
United States, Massachusetts
Novo Nordisk Investigational Site
Boston, Massachusetts, United States, 02115-5804
Novo Nordisk Investigational Site
Boston, Massachusetts, United States, 02118
United States, Montana
Novo Nordisk Investigational Site
Kalispell, Montana, United States, 59901
United States, New York
Novo Nordisk Investigational Site
New Windsor, New York, United States, 12553
United States, North Carolina
Novo Nordisk Investigational Site
Greenville, North Carolina, United States, 27834
Novo Nordisk Investigational Site
Statesville, North Carolina, United States, 28625
United States, Ohio
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45245
Novo Nordisk Investigational Site
Toledo, Ohio, United States, 43614
United States, South Carolina
Novo Nordisk Investigational Site
Pelzer, South Carolina, United States, 29669
United States, South Dakota
Novo Nordisk Investigational Site
Dakota Dunes, South Dakota, United States, 57049
United States, Tennessee
Novo Nordisk Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
Novo Nordisk Investigational Site
Amarillo, Texas, United States, 79106
Novo Nordisk Investigational Site
Kerrville, Texas, United States, 78028
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78215
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78224
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78228-6205
Canada, Alberta
Novo Nordisk Investigational Site
Calgary, Alberta, Canada, T2H 2G4
Canada, British Columbia
Novo Nordisk Investigational Site
Victoria, British Columbia, Canada, V8V 4A1
Canada, Ontario
Novo Nordisk Investigational Site
Concord, Ontario, Canada, L4K 4M2
Novo Nordisk Investigational Site
Etobicoke, Ontario, Canada, M9R 4E1
Novo Nordisk Investigational Site
London, Ontario, Canada, N5W 6A2
Novo Nordisk Investigational Site
Markham, Ontario, Canada, L3P 7P2
Novo Nordisk Investigational Site
Oakville, Ontario, Canada, L6M 1M1
Novo Nordisk Investigational Site
Toronto, Ontario, Canada, M4G 3E8
Novo Nordisk Investigational Site
Toronto, Ontario, Canada, M6G 1M2
Canada, Quebec
Novo Nordisk Investigational Site
Montreal, Quebec, Canada, H4A 2C6
Poland
Novo Nordisk Investigational Site
Bialystok, Poland, 15-351
Novo Nordisk Investigational Site
Bialystok, Poland, 15-404
Novo Nordisk Investigational Site
Gdansk, Poland, 80-858
Novo Nordisk Investigational Site
Lublin, Poland, 20-538
Novo Nordisk Investigational Site
Warszawa, Poland, 00-465
Puerto Rico
Novo Nordisk Investigational Site
Ponce, Puerto Rico, 00716
Slovakia
Novo Nordisk Investigational Site
Bratislava, Slovakia, 831 01
Novo Nordisk Investigational Site
Bratislava, Slovakia, 851 01
Novo Nordisk Investigational Site
Bytca, Slovakia, 014 01
Novo Nordisk Investigational Site
Levice, Slovakia, 93401
Novo Nordisk Investigational Site
Malacky, Slovakia, 901 01
Novo Nordisk Investigational Site
Nove Mesto nad Vahom, Slovakia, 915 01
Novo Nordisk Investigational Site
Nove Zamky, Slovakia, 940 59
Novo Nordisk Investigational Site
Trebisov, Slovakia, 07501
Novo Nordisk Investigational Site
Trnava, Slovakia, 91701
Novo Nordisk Investigational Site
Zilina, Slovakia, 010 01
South Africa
Novo Nordisk Investigational Site
Port Elizabeth, Eastern Cape, South Africa, 6045
Novo Nordisk Investigational Site
Bloemfontein, Free State, South Africa, 9301
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa, 1827
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa, 1829
Novo Nordisk Investigational Site
Lenasia, Gauteng, South Africa, 1827
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa, 0044
Novo Nordisk Investigational Site
Cape Town, Western Cape, South Africa, 7130
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S

Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT03687827    
Other Study ID Numbers: NN1250-4419
U1111-1203-0580 ( Other Identifier: World Health Organization (WHO) )
2017-004047-20 ( Registry Identifier: European Medicines Agency (EudraCT) )
First Posted: September 27, 2018    Key Record Dates
Last Update Posted: March 6, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
URL: http://novonordisk-trials.com/sharing-results

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs